On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Patent Portfolio to 43 Granted Patents Worldwide

  • Lexaria recently received two new patents granted in the U.S. in its patent families #21 and #24
  • The new patents complement the company’s efforts in investigating the capabilities of DehydraTECH-CBD to lower blood pressure in humans with hypertension and mitigate epileptic seizures in rodents
  • The company relies on R&D to provide data that enables it to apply for patent protection, supports further investigations and discoveries, as well as increases its chances of potentially receiving FDA approvals
  • According to CEO Chris Bunka, the company’s growing patent portfolio forms the foundation upon which the company forges commercial relationships

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, started 2024 with a portfolio of 38 patents granted worldwide, having received ten new granted patents during 2023, the most yet in a single year. That patent portfolio, company CEO Chris Bunka explained in his 2024 letter to shareholders, provides vital support for Lexaria’s commercialization efforts as it forms “the foundation upon which future commercial relationships are built.” Yet, according to the letter, the company continues to expect additional patents to be awarded in the future and retains many valid patent applications throughout the world (https://cnw.fm/Bb3nv).

This year, the company has received five new patents, growing its portfolio to 43 granted patents worldwide. This follows the April receipt of three new patents and the most recent announcement of two important new patent awards captured in a May 2024 news release.

According to the announcement, Lexaria received a new granted patent in its patent family #21: Compositions and Methods for Treating Hypertension. This is the company’s third granted U.S. patent in this patent family. Lexaria also reported the receipt of a new granted patent in its patent family #24: Compositions and Methods for Treating Epilepsy. This is the company’s third granted U.S. patent in this patent family (https://cnw.fm/6eFfU).

The company’s growing list of granted patents results from early and ongoing R&D. According to Mr. Bunka, Lexaria uses study-dependent data from studies to confidently support its patent applications. But besides serving the “purpose of allowing us to more confidently apply for patent protection using the study-dependent data,” the studies provide data to potentially support further investigations and discoveries, as well as potential approvals by the U.S. Food and Drug Administration (“FDA”).

This approach, coupled with the long-term vision, has enabled the company to investigate the capabilities of various active pharmaceutical ingredients processed using its patented DehydraTECH(TM) drug delivery technology in human and animal studies. For instance, Lexaria has investigated the ability of DehydraTECH-processed cannabidiol (“CBD”) to potentially treat hypertension in humans and mitigate epileptic seizures in rodents. These applications are partly or wholly protected by the recently granted patents.

Lexaria has repeatedly demonstrated that DehydraTECH-CBD has shown an ability to lower blood pressure in both acute dosing in hypertension and over a 5-week study duration. In a series of four hypertension studies, the company evidenced DehydraTECH-CBD’s ability to lower human blood pressure (https://cnw.fm/YuYG6), including in cases where the treatment was administered over an extended period (https://cnw.fm/ukRzo). The fourth study also led to the discovery of a potentially novel mechanism of action of DehydraTECH-CBD (https://cnw.fm/MjOjt).

These positive results encouraged the company to begin the process of seeking approval from the FDA to conduct a Phase 1b randomized, double-blind, placebo-controlled study of the safety, pharmacokinetics, and pharmacodynamics of DehydraTECH-CBD for the treatment of stage 1 or 2 hypertension. The company received earlier this year the FDA clearance to conduct the study (https://cnw.fm/Yo9IO) and will provide updates on the status of this planned study in due course.

Beyond the treatment of hypertension, Lexaria has demonstrated, through an animal study, that DehydraTECH-CBD reduces or eliminates seizure activity in animals and, in some cases, even surpasses the performance of Epidiolex(R), one of the world’s leading anti-seizure medications. The company also reported that DehydraTECH-CBD suppresses body weight, improves triglyceride/cholesterol levels, and reduces blood glucose levels in an animal diabetes study.

The successes of these animal studies have supported the possibility of conducting additional human clinical studies of DehydraTECH-CBD. In addition to investigating DehydraTECH-CBD’s capabilities, Lexaria is also looking at the potential application of its drug delivery technology to GLP-1 drugs.

Supported by a robust growing portfolio of granted patents and encouraged by the positive results from its R&D activities, Lexaria continues to forge ahead, aiming to achieve its future business objectives.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Archives

Select A Month

Official NewsWire Relationships

Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition Cannexpo Marigold PR MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo Tether BudTender Tether BudTender Appreciation Week

CannabisNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722